Margin dodolan resik: sunshinebiopharma.com (SBFM)

Lambang korporat lan logo Sunshine Biopharma (SBFM)

Sunshine Biopharma (SBFM) is susceptible to disruptions in global reagent supplies and geopolitical barriers during drug registration. The company's sales margins demonstrate current operational resilience, where the parameter equals -17.40. The development of a small-molecule platform to combat tumor resistance creates unique value, although liquidity shortages and early-stage research risks could lead to equity dilution.

Sunshine Biopharma, Inc. (SBFM) - Margin dodolan perusahaan saka 04.07.2022 nganti 19.11.2026

Rincian analitis perusahaan Sunshine Biopharma

- nilai pasar lan prakiraan target analis:
Ringkesan analitik perusahaan:Sunshine Biopharma, Inc. - SBFM
Barang unggulan Sunshine Biopharma Inc.

Net margin captures the portion of profit remaining with the business after covering all operating and financial obligations. This metric serves as a stress-testing tool for capital resilience against internal costs. The current sales margin level -17.40 reflects Sunshine Biopharma's critical dependence on external financing. A lack of pricing power and proprietary revenue streams renders this indicator negative. Investors should interpret such values as an indicator of venture risk inherent in clinical biotech.

Pesaing langsung

ONC: Margin dodolan resik|Margin resik Halozyme Inc. (HALO)|Margin resik RevMed|Rentabilitas dodolan resik AAPG (Ascentage Pharma Group)|Margin dodolan resik CGON|UroGen Pharma - Rentabilitas dodolan resik|Bicara Therapeutics - Rentabilitas dodolan miturut bathi resik|Margin dodolan resik Personalis Inc PSNL|Erasca Oncology - Margin dodolan resik|Tingkat bathi resik DCTH (Delcath Corp)|YMAB: Margin dodolan resik|AURA - Margin dodolan perusahaan|CADL (Candel Therapeutics Inc.) - Margin dodolan resik|Rentabilitas dodolan resik ARAY (Accuray)|Rentabilitas dodolan miturut bathi resik SLS (SELLAS Life Sciences Group, Inc.)|ACTU - Margin resik|Margin resik Citius Oncology, Inc. CTOR|HURA - Rentabilitas dodolan miturut bathi resik|protaratx.com - Margin dodolan resik|FATE - Margin dodolan resik|WHWK: Margin dodolan resik|TScan Therapeutics (TCRX) - Margin dodolan resik|Margin resik Champions Oncology|Margin resik XBIT|Margin dodolan resik CVM|Rentabilitas dodolan miturut bathi resik OS Therapies Inc. OSTX|Margin resik Radiopharm Theranostics Limited RADX|artivabio.com (ARTV) - Margin resik|ANL - Margin resik|Margin resik verupharma.com|TPST: Margin dodolan resik|XLO - Margin dodolan perusahaan|Margin resik Renovaro|Margin dodolan resik muraloncology.com|Margin dodolan resik KAPA|Margin dodolan perusahaan OnKure Therapeutics, Inc.|Margin dodolan resik GDTC (w2.cytomed.sg)|CRIS - Rentabilitas dodolan miturut bathi resik|Apollomics - Margin dodolan resik|Tharimmune Corp (THAR) - Rentabilitas dodolan miturut bathi resik|ADVB: Margin dodolan resik|Rentabilitas dodolan miturut bathi resik Genprex|CLDI (Calidi Biotherapeutics, Inc.) - Margin dodolan resik|Margin dodolan resik xeneticbio.com|Margin resik Salarius (SLRX)|Rentabilitas dodolan miturut bathi resik Purple Biotech PPBT|Margin resik American Oncology Network, Inc. AONC|BeiGene, Ltd. (BGNE) - Margin resik|Checkpoint Therapeutics Inc. - Margin dodolan resik|Tingkat bathi resik ELEV (Elevation Oncology)|ICAD (iCAD Corp) - Rentabilitas dodolan miturut bathi resik|Ikena Oncology, Inc. - Tingkat bathi resik|Rentabilitas dodolan miturut bathi resik NTBL|VIRX: Tingkat bathi resik|Margin resik MorphoSys Corporation (MOR)|NAYA - Margin resik|Margin dodolan resik AAPGV (Ascentage)